Taken together, the news out of the second- and third-biggest drugmakers could represent an argument for more pharmaceutical megamergers. GlaxoSmithKline has finally turned its heritage into a pipeline of new medicines. Meanwhile, merger-eschewing Merck may struggle to make existing estimates.
